125 related articles for article (PubMed ID: 8409683)
1. An evaluation of the effectiveness and safety of razoxane when used as an adjunct to surgery in colo-rectal cancer. Report of a controlled randomised study of 603 patients.
Kingston RD; Fielding JW; Palmer MK
Int J Colorectal Dis; 1993 Jul; 8(2):106-10. PubMed ID: 8409683
[TBL] [Abstract][Full Text] [Related]
2. Peri-operative heparin: a possible adjuvant to surgery in colo-rectal cancer?
Kingston RD; Fielding JW; Palmer MK
Int J Colorectal Dis; 1993 Jul; 8(2):111-5. PubMed ID: 8409684
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of oral adjuvant razoxane (ICRF 159) in resectable colorectal cancer: five-year follow-up.
Gilbert JM; Hellmann K; Evans M; Cassell PG; Taylor RH; Stoodley B; Ellis H; Wastell C
Br J Surg; 1986 Jun; 73(6):446-50. PubMed ID: 3521784
[TBL] [Abstract][Full Text] [Related]
4. A controlled prospective trial of adjuvant razoxane in resectable colorectal cancer.
Gilbert JM; Cassell PC; Ellis H; Wastell C; Hellmann K; Evans MG; Stoodley BJ
Recent Results Cancer Res; 1981; 79():48-58. PubMed ID: 7029684
[TBL] [Abstract][Full Text] [Related]
5. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
6. A small prospective study of chordomas treated with radiotherapy and razoxane.
Rhomberg W; Böhler FK; Novak H; Dertinger S; Breitfellner G
Strahlenther Onkol; 2003 Apr; 179(4):249-53. PubMed ID: 12707714
[TBL] [Abstract][Full Text] [Related]
7. Sister chromatid exchange (SCE) frequency in lymphocytes of patients with colorectal carcinoma treated with razoxane.
Price CM; Hagger D; Evans M; Kanfer EJ; Shepherd J; Topham C; Cassell PG; Haworth C
Cancer Detect Prev; 1992; 16(4):221-3. PubMed ID: 1458513
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant oral razoxane (ICRF-159) in resectable colorectal cancer.
Gilbert JM; Hellmann K; Evans M; Cassell PG; Stoodley B; Ellis H; Wastell C
Cancer Chemother Pharmacol; 1982; 8(3):293-9. PubMed ID: 7127660
[TBL] [Abstract][Full Text] [Related]
9. Effect of razoxane on metastases from colorectal cancer.
Hellmann K; Gilbert J; Evans M; Cassell P; Taylor R
Clin Exp Metastasis; 1987; 5(1):3-8. PubMed ID: 3829494
[TBL] [Abstract][Full Text] [Related]
10. Irradiation with and without razoxane in the treatment of incompletely resected or inoperable recurrent rectal cancer. Results of a small randomized multicenter study.
Rhomberg W; Hammer J; Sedlmayer F; Eiter H; Seewald D; Schneider B
Strahlenther Onkol; 2007 Jul; 183(7):380-4. PubMed ID: 17609871
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study.
Rhomberg W; Hassenstein EO; Gefeller D
Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1077-84. PubMed ID: 8985029
[TBL] [Abstract][Full Text] [Related]
12. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukaemia after treatment with razoxane.
Caffrey EA; Daker MG; Horton JJ
Br J Dermatol; 1985 Aug; 113(2):131-4. PubMed ID: 3861193
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of post-operative recurrence of colorectal cancer].
Kodaira S
Nihon Geka Gakkai Zasshi; 1999 Feb; 100(2):206-10. PubMed ID: 10331220
[TBL] [Abstract][Full Text] [Related]
15. Aspects of survival from colorectal cancer in Denmark.
Iversen LH
Dan Med J; 2012 Apr; 59(4):B4428. PubMed ID: 22459726
[TBL] [Abstract][Full Text] [Related]
16. Prospective serial liver ultrasound scanning in resectable colorectal cancer treated with adjuvant razoxane.
Taylor RH; Gilbert JM; Evans MG; Lane HG; Cassell PG
Clin Exp Metastasis; 1984; 2(4):321-31. PubMed ID: 6399698
[TBL] [Abstract][Full Text] [Related]
17. Inoperable recurrent rectal cancer: results of a prospective trial with radiation therapy and razoxane.
Rhomberg W; Eiter H; Hergan K; Schneider B
Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):419-25. PubMed ID: 7523346
[TBL] [Abstract][Full Text] [Related]
18. Phase I-II evaluation of razoxane (ICRF-159) and doxorubicin in gastrointestinal cancer. A Southeastern Cancer Study Group Trial.
DeSimone PA; Greco FA; Omura GA; Bartolucci A
Am J Clin Oncol; 1986 Jun; 9(3):185-6. PubMed ID: 3728369
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
[TBL] [Abstract][Full Text] [Related]
20. Post-surgery morbidity and mortality in colorectal cancer in elderly subjects.
Savlovschi C; Serban D; Trotea T; Borcan R; Dumitrescu D
Chirurgia (Bucur); 2013; 108(2):177-9. PubMed ID: 23618565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
